I would have to agree on both points. What is normal? If someone is below or above average height is there something wrong with them? It is change that is important especially for glaucoma however many patients have thickness changes that have nothing to do with glaucoma so it important to communicate that. It is the second part that I find most interesting. Most of the work I do is for retina. We also have 4 glaucoma docs. I am seeing more patients cycling from retina to glaucoma. With some of them you can easily see the diffidence in the optic nerve over a course of a few years. So much for you will only lose your central vision if you have AMD. The question I have is would they have had glaucoma eventually and this is just accelerating the process or is this actually causing glaucoma? It is a question that needs further study. Chris Carlton VGH/UBC Eye Care Center ________________________________ From: optimal-bounce@xxxxxxxxxxxxx [mailto:optimal-bounce@xxxxxxxxxxxxx] On Behalf Of Gregory Hoffmeyer Sent: Wednesday, August 13, 2014 5:45 PM To: optimal@xxxxxxxxxxxxx Subject: [optimal] Re: question about OCT-C Certification - RED DISEASE Beware or normative data-induced "RED DISEASE" - whereas a given normative dbase may flag physiologically healthy retina tissue as abnormal when there really is nothing going on. I agree with Tim as well - it's mostly about change over time and of course the complete eye exam. Also, don't forget ganglion cell analysis if your device performs such - at times it takes some convincing for non-retina docs to scan the macula and conversely, retina docs to scan the nerve - there are discussions re accelerating glaucoma with serial anti VEGF injections - - - pick your poison I guess... Scanning and billing both the same day another discussion. ---------------------------------------- This message is intended for a particular addressee only and may contain business or company secrets. If you have received this email in error, please contact the sender and delete the message immediately. Any use of this email, including saving, publishing, copying, replication or forwarding of the message or the contents is not permitted.